Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Toll-Like Receptors (Tlrs): An Old Family of Immune Receptors With a New Face in Cancer Pathogenesis Publisher Pubmed



Mokhtari Y1 ; Pourbagherisigaroodi A1 ; Zafari P2, 3 ; Bagheri N4 ; Ghaffari SH5 ; Bashash D1
Authors

Source: Journal of Cellular and Molecular Medicine Published:2021


Abstract

In the dark path of tumorigenesis, the more carefully the cancer biology is studied, the more brilliant answers could be given to the countless questions about its orchestrating derivers. The identification of the correlation between Toll-like receptors (TLRs) and different processes involved in carcinogenesis was one of the single points of blinding light highlighting the interconnection between the immune system and cancer. TLRs are a wide family of single-pass membrane-spanning receptors that have developed through the evolution to recognize the structurally conserved molecules derived from microorganisms or damaged cells. But this is not everything about these receptors as they could orchestrate several downstream signalling pathways leading to the formation or suppression of cancer cells. The present review is tempted to provide a concise schematic about the biology and the characters of TLRs and also summarize the major findings of the regulatory role of TLRs and their associated signalling in the pathogenesis of human cancers. © 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd
Other Related Docs
8. Toll-Like Receptors, Encyclopedia of Infection and Immunity (2022)
9. Toll-Like Receptor Pathway and Its Targeting in Treatment of Cancers, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
10. Toll-Like Receptor Pathway and Its Targeting in Treatment of Cancers, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers (2015)
14. The Yin and Yang of Toll-Like Receptors in Endothelial Dysfunction, International Immunopharmacology (2022)